MedTrace Logo

Prospective Evaluation of Adjusted Body Weight Dosing of Acyclovir in Obesity

NCT02879630 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2026-04-16

No results posted yet for this study

Summary

Patients receiving acyclovir as standard of care will be enrolled into this study. The currently recommended dosing strategy at our institution for obese patients is to receive intravenous acyclovir dosed per an adjusted body weight \[IBW + 0.4(TBW-IBW)\]. They will have blood drawn once prior to the first dose of acyclovir and 10 times thereafter, over a total time period of 12 hours. These patients will already be hospitalized for other reasons, and will not be required to make additional trips to the hospital. A total of approximately 4-5 tablespoons of blood will be drawn for this study. Ten obese patients and 10 matched control (non-obese) patients will be enrolled.

Conditions

Sponsors & Collaborators

  • West Virginia University

    lead OTHER

Principal Investigators

  • Aaron Cumpston, PharmD, BCOP · West Virginia University Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-28
Primary Completion
2026-02-16
Completion
2026-02-16

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02879630 on ClinicalTrials.gov